Skip to content
Home
Visit our other Journals
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Diseases
Alzheimer's Disease
Dementia
Dementia with Lewy Bodies
Frontotemporal Dementia
Vascular Dementia
Mild Cognitive Impairment
View all Diseases
Topics
Diagnostics
Biology
Biomarkers
Treatment
Clinical Care
Prevention
View all Topics
Conferences
AAIC 2023
BNA 2023
AD/PD 2023
ARUK 2023
CTAD 2022
AAIC 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
CTAD 2022 and Lecanemab
View overview page
3:02
Lecanemab: drawbacks to consider
Alvaro Pascual-Leone
• 9 Jan 2023
5:24
Lecanemab: a review
Alvaro Pascual-Leone
• 9 Jan 2023
2:10
FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis?
Alvaro Pascual-Leone
• 9 Jan 2023
1:35
Lecanemab vs aducanumab
Alvaro Pascual-Leone
• 9 Jan 2023
3:55
Highlights from CTAD 2022
Jacques Touchon
• 9 Dec 2022
5:48
Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk
Nicolas Villain
• 6 Dec 2022
2:24
Lecanemab and what this means for the future treatment of Alzheimer’s disease
Jesse Cedarbaum
• 1 Dec 2022
5:40
Future direction for anti-amyloid immunotherapies
Nicolas Villain
• 6 Dec 2022
5:02
The Phase III NILEAD trial: nilotinib as a novel treatment for AD
Charbel Moussa
• 28 Nov 2022
